| Market Cap | $33.01M-18.6% |
| Revenue (ttm) | $35.00M |
| Net Income | $10.60M |
| EPS | $0.43 |
| Shares Out | 31.44M |
| PE Ratio | 2.44 |
| Forward PE | -2.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 280,659 |
| Open | $1.07 |
| Previous Close | $1.07 |
| Day's Range | $1.00 - $1.10 |
| 52-Week Range | $0.73 - $1.72 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | $4.50(+328.57%) |
| Earnings Date | n/a |
About ATNM
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
$ATNM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ATNM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ATNM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ATNM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ATNM Revenue by Segment
| Recognized upfront payment | $35.00M | 24.98% |
| Other revenue | $35.00M | 24.98% |
| Claim amount | $35.00M | 24.98% |
| Non-refundable payment received | $35.00M | 24.98% |
| Grant revenue | $100.00K | 0.07% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ATNM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ATNM from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ATNM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple positive clinical trial milestones, SAB formation, and progress on lead asset ATNM-400 demonstrate pipeline advancement without negative catalysts.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
